• Founder’s Vision
  • ANKTIVA
  • BCG
  • Our Science
  • Careers
  • Contact
ImmunityBio
  • Patients & Caregivers
    • ANKTIVA®
    • Clinical Trials
    • Patients
    • Therapeutic Areas
      • Bladder Cancer
      • Glioblastoma
      • HIV
      • Human Papillomavirus
      • Lymphopenia
      • Lynch Syndrome
      • Non-Hodgkin Lymphoma
      • Non-Small Cell Lung Cancer
      • Ovarian Cancer
  • Healthcare Providers
    • ANKTIVA®
    • Clinical Trials
    • Trial Investigators
    • Expanded Access
  • Researchers
    • Platforms & Modalities
    • Trial Investigators
    • Cell Licensing
    • Publications
  • Our Company
    • About
    • Pipeline
    • Contact
    • Compliance & Transparency
  • News and Events
  • Investors
Select Page

Recent Posts

  • ImmunityBio Reports Net Product Revenue Increased Nearly 2.7 Times Year-Over-Year to Record $44 Million in Q1 2026 and $381 Million in Cash and Marketable Securities
  • ImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance
  • ImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million of Non-Dilutive Financing to Support Global Expansion and Advancement of Broader Immunotherapy Pipeline
  • ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA® Plus BCG Versus BCG Alone; Supplemental BLA Submission on Track for 2026
  • Goldman Sachs 47th Annual Global Healthcare Conference 2026
 

 

 

Please be aware of fraudulent activity by individuals, organizations, or websites that falsely claim to represent ImmunityBio in connection with clinical trial recruitment or commercial activities. Learn more

[Clinical Trials] We have an established process, governed by regulatory authorities, that is required for individuals seeking access to our Clinical Trials or approved therapies. Information on our trials is available directly through our Find a Clinical Trial page on our website or at the https://clinicaltrials.gov/website. ImmunityBio accepts no responsibility for any costs or charges incurred as a result of fraudulent activity.

[Recruitment activities] We have an established process required for all positions prior to issuing an offer of employment. The process requires formal interviews with members of our team and never requires payments or fees from job applicants. We do not conduct interviews via messaging tools like WhatsApp, Signal, etc. Qualified and interest candidates should apply to current openings directly through our careers page on the ImmunityBio website. ImmunityBio accepts no responsibility for any costs or charges incurred as a result of fraudulent activity.

In the event you receive a suspicious message – via email, WhatsApp, or text, etc. – we advise against providing any personal information or paying any fees. If you have lost money or provided your personal identifying information, please contact your bank and report the matter to the US Federal Bureau of Investigation (FBI) via www.ic3.gov.

Quicklinks

  • Pipeline
  • Careers
  • News and Events
  • Investors
  • Contact

Follow Us

  •  Facebook
  •  X
  •  LinkedIn

Legal

  • Privacy Policy
  • Legal Notice
  • Patent Notice
  • How-To-Use-Accessibe

© 2026 ImmunityBio, Inc. All Rights Reserved.

A member of the NantWorks ecosystem of companies

’ImmunityBio’, ‘ImmunityBio Care’, 'Anktiva’, ‘ThAnktiva’, ‘haNK’, ‘taNK’, ‘ceNK’, ‘NK-92’, ‘Nant Cancer Vaccine’, ‘NANT 001’, ‘NANT XL’, ‘NANT 001 and Design’, ‘QUILT’, ‘Outsmart Your Disease’, ‘Smart Therapies for Difficult Diseases’, ‘Nantkwest’, ‘VivaBioCell’, and ‘Infacell’ are trademarks or registered trademarks of ImmunityBio, Inc., its subsidiaries and affiliates.

The Natural Killer Cell platform consists of investigational agents that are restricted by federal law to investigational use only.

The Natural Killer Cell platform is being investigated in multiple clinical trials across tumor sites.

The content of this website is protected by Title 17 of the U.S. Code and may not be reproduced in whole or in part by any means.

Sitemap